Hanall Biopharma and Daewoong Pharmaceutical Invest in US Cell Reprogramming New Drug Development Company

원본보기 아이콘

[Asia Economy Reporter Lee Gwan-joo] HanAll BioPharma and Daewoong Pharmaceutical announced on the 12th that they have signed an investment contract with the U.S. Silicon Valley-based biotech company Turn Biotechnologies.

Turn Bio is a biotech company researching 'cell reprogramming' technology that reverses the biological clock of cells. It was founded in 2018 by a research team led by Dr. Vittorio Sebastiano of Stanford University School of Medicine. Currently, it is conducting preclinical studies on diseases caused by aging in various fields such as dermatology, immunology, and ophthalmology.

Turn Bio's patented platform, 'ERATM (Epigenetic Reprogramming of Age),' has a mechanism that restores aged cells to a youthful state. It injects protein factors that regulate genes in the form of mRNA into cells to restore cell function or induce repair of damaged tissues.

HanAll BioPharma and Daewoong Pharmaceutical have previously strengthened their new drug development capabilities by investing in biotech companies with innovative drug development capabilities and potential, such as Alloplex Biotherapeutics and Nurron Pharmaceuticals, to secure global growth engines. Taking this investment as an opportunity, the two companies plan to seek mid- to long-term cooperation opportunities for developing therapeutics using Turn Bio's cell reprogramming platform.

Seungwon Jung, CEO of HanAll BioPharma, said, "We expect that by applying Turn Bio's platform to the areas of eye diseases and immune diseases that HanAll BioPharma is focusing on, we can offer hope to patients suffering from intractable diseases," and added, "We will continue active investments to expand open collaboration in the global market."

Anya Kramer, CEO of Turn Bio, said, "This funding recognizes the potential of Turn Bio's cell reprogramming technology for new drug development," and added, "We appreciate the interest and support of HanAll BioPharma and Daewoong Pharmaceutical, and we look forward to contributing to improving the quality of life of patients worldwide through more collaborations."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.